Annals of Oncology
Latest Publications

TOTAL DOCUMENTS

48389

(FIVE YEARS 12204)

H-INDEX

222

(FIVE YEARS 46)

Published By Oxford University Press

1569-8041, 0923-7534

Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

Homologous recombination deficiency testing in first-line ovarian cancer

Annals of Oncology ◽

10.1016/j.annonc.2021.12.013 ◽

2022 ◽

Author(s):

K.N. Moore ◽

A. du Bois

Keyword(s):

Ovarian Cancer ◽

Homologous Recombination ◽

First Line ◽

Homologous Recombination Deficiency

Download Full-text

The upper ECHELON against T-cell lymphoma

Annals of Oncology ◽

10.1016/j.annonc.2021.12.011 ◽

2022 ◽

Author(s):

Emmanuel Bachy ◽

Gilles Salles

Keyword(s):

T Cell ◽

Cell Lymphoma ◽

T Cell Lymphoma ◽

Upper Echelon

Download Full-text

Corrigendum to “Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria”

Annals of Oncology ◽

10.1016/j.annonc.2022.01.001 ◽

2022 ◽

Author(s):

J.J. Gao ◽

D. Krol ◽

P. Narayan ◽

F. Cardoso ◽

M.M. Regan ◽

...

Keyword(s):

Breast Cancer ◽

Premenopausal Women ◽

Eligibility Criteria

Download Full-text

Dabrafenib plus trametinib in patients with BRAF V600E–mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Annals of Oncology ◽

10.1016/j.annonc.2021.12.014 ◽

2022 ◽

Author(s):

V. Subbiah ◽

R.J. Kreitman ◽

Z.A. Wainberg ◽

J.Y. Cho ◽

J.H.M. Schellens ◽

...

Keyword(s):

Thyroid Cancer ◽

Phase Ii ◽

Anaplastic Thyroid Cancer ◽

Braf V600e

Download Full-text

Editorial Board

Annals of Oncology ◽

10.1016/s0923-7534(21)04837-7 ◽

2022 ◽

Vol 33 (1) ◽

pp. iii

Download Full-text

Improving Access to Immunotherapy in Low and Middle-Income Countries

Annals of Oncology ◽

10.1016/j.annonc.2022.01.003 ◽

2022 ◽

Author(s):

A. Patel ◽

D.A. Goldstein ◽

I.F. Tannock

Keyword(s):

Middle Income ◽

Middle Income Countries ◽

Low And Middle Income

Download Full-text

Thanks to referees 2021

Annals of Oncology ◽

10.1016/j.annonc.2021.10.012 ◽

2022 ◽

Vol 33 (1) ◽

pp. 1-3

Download Full-text

Annals of Oncology ◽

10.1016/s0923-7534(21)04836-5 ◽

2022 ◽

Vol 33 (1) ◽

pp. i-ii

Download Full-text

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: First-in-human dose-escalation study

Annals of Oncology ◽

10.1016/j.annonc.2021.12.012 ◽

2022 ◽

Author(s):

A. Gazzah ◽

P.L. Bedard ◽

C. Hierro ◽

Y.-K. Kang ◽

A. Abdul Razak ◽

...

Keyword(s):

Antitumor Activity ◽

Solid Tumors ◽

Dose Escalation ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Dose Escalation Study ◽

Drug Conjugate ◽

Human Dose ◽

Antibody Drug

Download Full-text

External Control Arms in Oncology: Current Use and Future Directions

Annals of Oncology ◽

10.1016/j.annonc.2021.12.015 ◽

2022 ◽

Author(s):

P.S. Mishra-Kalyani ◽

L. Amiri Kordestani ◽

D.R. Rivera ◽

H. Singh ◽

A. Ibrahim ◽

...

Keyword(s):

External Control ◽

Future Directions

Download Full-text

Annals of Oncology
Latest Publications

TOTAL DOCUMENTS

H-INDEX

Published By Oxford University Press

Homologous recombination deficiency testing in first-line ovarian cancer

The upper ECHELON against T-cell lymphoma

Corrigendum to “Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria”

Dabrafenib plus trametinib in patients with BRAF V600E–mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Editorial Board

Improving Access to Immunotherapy in Low and Middle-Income Countries

Thanks to referees 2021

Table of Contents

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: First-in-human dose-escalation study

External Control Arms in Oncology: Current Use and Future Directions

Export Citation Format

Annals of OncologyLatest Publications

TOTAL DOCUMENTS

H-INDEX

Published By Oxford University Press

Homologous recombination deficiency testing in first-line ovarian cancer

The upper ECHELON against T-cell lymphoma

Corrigendum to “Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria”

Dabrafenib plus trametinib in patients with BRAF V600E–mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Editorial Board

Improving Access to Immunotherapy in Low and Middle-Income Countries

Thanks to referees 2021

Table of Contents

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: First-in-human dose-escalation study

External Control Arms in Oncology: Current Use and Future Directions

Annals of Oncology
Latest Publications